BioCentury | Jun 11, 2012
Company News

Agendia sales and marketing update

...launched its colon cancer recurrence test ColoPrint for stage II colon cancer prognosis and prediction. ColoPrint...
BioCentury | Jun 4, 2012
Finance

Agendia's private party

...determine the best therapeutic approaches for breast cancer patients. Last week, the company launched its ColoPrint...
BioCentury | Jun 1, 2012
Financial News

Agendia raises $65 million

...therapeutic approaches for breast cancer patients. The company is also conducting validation testing for the ColoPrint...
BioCentury | Jun 13, 2011
Finance

Agendia's agenda

...particularly in the U.S. - and to complete validation and start commercialization of its ColoPrint...
BioCentury | Jun 13, 2011
Company News

Agendia B.V., The Netherlands Cancer Institute, University of Texas deal

...diagnosis and treatment options for colorectal cancer. The collaboration will allow Agendia to validate its ColoPrint...
BioCentury | May 23, 2011
Finance

Euro IPOs

...and marketing, particularly in the U.S., and to complete validation and start commercialization of its ColoPrint...
BioCentury | Jun 14, 2010
Clinical News

ColoPrint diagnostic data

...tumor tissue samples from 137 patients who underwent curative resection for stage II colorectal cancer, ColoPrint...
...predict the development of distant metastasis (p=0.007). In patients identified as low-risk and high-risk by ColoPrint...
...distant metastasis (p=0.2) and did not add power to the ColoPrint classification. Risk assessment by ColoPrint...
BioCentury | Jun 8, 2009
Clinical News

ColoPrint: Pilot trial data

...tissue samples from 180 patients with stage I, II and III colorectal cancer undergoing surgery, ColoPrint...
...American Society of Clinical Oncology meeting in Orlando. Agendia B.V. , Amsterdam, the Netherlands Product: ColoPrint...
Items per page:
1 - 8 of 8